If you have been reading about REV-ERB agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-05-25. Numbers and descriptions here follow the published literature rather than marketing material.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
=== Insulin structure === Insulin was one of Hodgkin's most extraordinary research projects. It began in 1934 when she was offered a small sample of crystalline insulin by Robert Robinson. The hormone captured her imagination because of the intricate and wide-ranging effect it has in the body. However, at this stage X-ray crystallography had not been developed far enough to cope with the complexity of the insulin molecule. She and others spent many years improving the technique. It took 35 years after taking her first photograph of an insulin crystal for X-ray crystallography and computing techniques to be able to tackle larger and more complex molecules like insulin. Hodgkin's dream of unlocking the structure of insulin was put on hold until 1969 when she was finally able to work with her team of young, international scientists to uncover the structure for the first time. Hodgkin's work with insulin was instrumental in paving the way for insulin to be mass-produced and used on a large scale for treatment of both type one and type two diabetes. She went on to cooperate with other laboratories active in insulin research, giving advice, and traveling the world giving talks about insulin and its importance for the future of diabetes. Solving the structure of insulin had two important implications for the treatment of diabetes, both making mass production of insulin possible and allowing scientists to alter the structure of insulin to create even better drug options for patients going forward.
Field-flow fractionation, abbreviated FFF, is a separation technique invented by J. Calvin Giddings. The technique is based on separation of colloidal or high molecular weight substances in liquid solutions, flowing through the separation platform, which does not have a stationary phase. It is similar to liquid chromatography, as it works on dilute solutions or suspensions of the solute, carried by a flowing eluent. Separation is achieved by applying a field (hydraulic, centrifugal, thermal, electric, magnetic, gravitational, ...) or cross-flow, perpendicular to the direction of transport of the sample, which is pumped through a long and narrow laminar channel. The field exerts a force on the sample components, concentrating them towards one of the channel walls, which is called accumulation wall. The force interacts with a property of the sample, thereby the separation occurs, in other words, the components show differing "mobilities" under the force exerted by the crossing field. As an example, for the hydraulic, or cross-flow FFF method, the property driving separation is the translational diffusion coefficient or the hydrodynamic size. For a thermal field (heating one wall and cooling the other), it is the ratio of the thermal and the translational diffusion coefficient.
==== Milestones of 1,500 RBI, 1,500 runs scored and 200 stolen bases (2004) ==== When he hit his sixth career grand slam against Milwaukee on April 9, 2004, Bagwell tied a club record. He recorded his 200th career stolen base on August 30 against Cincinnati to become the tenth player in MLB history to reach that plateau while hitting 400 home runs. On September 18, 2004, Bagwell collected his 1,500th career RBI with a single in the third inning against the Brewers. Two innings later, he homered for his 1,500th run scored, becoming just the 29th player in MLB history and the first Astro to reach both milestones. Bagwell finished with 27 home runs, stopping a streak of eight consecutive seasons with at least 30, but extending a streak of 12 with at least 20. The Astros faced the Braves in the playoffs for the fourth time in Bagwell's career in the 2004 NLDS. In Game 3, on October 7, he hit his first career postseason home run off Mike Hampton in the first inning in a 4–2 extra-inning loss. After three failed attempts to advance past the first round of the playoffs earlier in Bagwell's career, losing to Atlanta in 1997, 1999, and 2001, and seven overall in 43 years of franchise history, the Astros defeated the Braves for their first-ever playoff series win. The quartet dubbed the "Killer B's," this time including Carlos Beltrán and Lance Berkman, ignited the Astros' offense, batting .395 (34-for-86) with eight home runs, 21 RBI and 24 runs scored. The Astros scored an NLDS-record 36 runs in all and Bagwell batted .318 with two home runs and five RBI.
=== L-Deprenyl === L-Deprenyl, sold under the brand name anipryl, does not target cortisol production, instead it directly addresses the tumour. Research on L-Deprenyl has shown that adrenocorticotropic hormone secretion in the intermediate area of the pituitary gland is controlled by the neurotransmitter dopamine. High levels of dopamine production will shut down adrenocorticotropic hormone secretion. L-Deprenyl inhibits the enzymes responsible for the degradation of dopamine as well as stimulating the production of dopamine. Approximately 5% of dogs experience minor nausea, restlessness, and reduced hearing ability. The different mechanism of L-Deprenyl and that it breaks down into amphetamine and methamphetamine—which suppresses hunger— meaning the normal monitoring tests are not useful in dogs treated with L-Deprenyl. Independent studies showed roughly 20% of dogs to improve with L-Deprenyl compared to 80% with studies sponsored by the manufacturer. Advantages of L-Deprenyl include the lower risk of side effects and inability to cause hypoadrenocoritism. Disadvantages are the substantial cost and the comparatively longer time before improvements can be noticed compared to lysodren. Some veterinarians may use high doses of lysodren to induce hypoadrenocorticism (a deficiency of cortisone), as it is easier to treat. This is not a common method and is not used in some hospitals.
An – actinide Some actinides can exist in several oxide forms such as An2O3, AnO2, An2O5 and AnO3. For all actinides, oxides AnO3 are amphoteric and An2O3, AnO2 and An2O5 are basic, they easily react with water, forming bases:
Sources: en.wikipedia.org
3-HM's levorotatory stereoisomer, norlevorphanol, in contrast to (+)-3-HM, is an opioid analgesic. It was never marketed as such however, probably due to a combination of the facts that norlevorphanol has low bioavailability and that its potency is diminished compared to its N-methylated analogue levorphanol.
== External links == Anorectics at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Mitchell, Kari (January 1997). "Anorexiant Agents: Considerations for Use" (PDF). Drug Therapy Topics. University of Washington Medical Center. Archived from the original (PDF) on 2013-12-26. Retrieved 25 December 2013.
In 2021, Kennedy opposed FEMA's effort to restructure its NFIP flood insurance program after changes the agency made caused insurance rates to skyrocket in Louisiana, prompting 8.5% of families to drop federal coverage. Kennedy said FEMA's Risk Rating 2.0 was "robbing Louisiana families of the flood protection they need for their homes". He has asked FEMA officials to disclose the algorithm used in Risk Rating 2.0 so it can demonstrate why rates increased 128% in Louisiana, but Millman, the firm that developed Risk Rating 2.0, and FEMA have refused to disclose the algorithm as of 2024. Kennedy introduced the Flood Insurance Pricing Transparency Act to try to force FEMA to disclose the information.
Protein Ser/Thr phosphatases were originally classified using biochemical assays as either, type 1 (PP1) or type 2 (PP2), and were further subdivided based on metal-ion requirement (PP2A, no metal ion; PP2B, Ca2+ stimulated; PP2C, Mg2+ dependent) (Moorhead et al., 2007). The protein Ser/Thr phosphatases PP1, PP2A and PP2B of the PPP family, together with PP2C of the PPM family, account for the majority of Ser/Thr PP activity in vivo (Barford et al., 1998). In the brain, they are present in different subcellular compartments in neuronal and glial cells, and contribute to different neuronal functions.
I begged the Red Sox not to trade you when you were in the minors with us. Boston's loss was Houston's gain. See you in Cooperstown." Three first bases were used in the game, each embossed with a commemorative insignia and inscription, "No. 5, Jeff Bagwell jersey retirement, Aug. 26, 2007." One was given to Bagwell and the other two were auctioned to raise funds on behalf of the Astros in Action Foundation. In 2009, Bagwell received the Bill Shea Distinguished Little League Graduate Award.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.